[go: up one dir, main page]

WO1996008270A3 - Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds - Google Patents

Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds Download PDF

Info

Publication number
WO1996008270A3
WO1996008270A3 PCT/US1995/011675 US9511675W WO9608270A3 WO 1996008270 A3 WO1996008270 A3 WO 1996008270A3 US 9511675 W US9511675 W US 9511675W WO 9608270 A3 WO9608270 A3 WO 9608270A3
Authority
WO
WIPO (PCT)
Prior art keywords
sexually transmitted
antimicrobials
magaining
transmitted diseases
squalamine
Prior art date
Application number
PCT/US1995/011675
Other languages
French (fr)
Other versions
WO1996008270A9 (en
WO1996008270A2 (en
Inventor
Leonard Jacob
Michael Zasloff
Taffy Williams
Gurrinder Bedi
Original Assignee
Magainin Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharma filed Critical Magainin Pharma
Priority to AU35125/95A priority Critical patent/AU3512595A/en
Publication of WO1996008270A2 publication Critical patent/WO1996008270A2/en
Publication of WO1996008270A3 publication Critical patent/WO1996008270A3/en
Publication of WO1996008270A9 publication Critical patent/WO1996008270A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Transmission of sexually transmitted disease is inhibited in humans by a method that comprises administering to a human one or more magainin antimicrobials or one or more squalamine compounds in an amount sufficient to inhibit transmission of sexually transmitted disease.
PCT/US1995/011675 1994-09-13 1995-09-13 Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds WO1996008270A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35125/95A AU3512595A (en) 1994-09-13 1995-09-13 Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30547594A 1994-09-13 1994-09-13
US08/305,475 1994-09-13

Publications (3)

Publication Number Publication Date
WO1996008270A2 WO1996008270A2 (en) 1996-03-21
WO1996008270A3 true WO1996008270A3 (en) 1996-05-17
WO1996008270A9 WO1996008270A9 (en) 1996-06-27

Family

ID=23180966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011675 WO1996008270A2 (en) 1994-09-13 1995-09-13 Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds

Country Status (2)

Country Link
AU (1) AU3512595A (en)
WO (1) WO1996008270A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
FR2744453B1 (en) * 1996-02-05 1998-07-10 Transgene Sa LIPOPOLYAMINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, NUCLEIC ACID TRANSFER VECTORS AND PREPARATION METHOD
US7410959B1 (en) 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
JP4340330B2 (en) * 1996-05-24 2009-10-07 アイシー‐ヴェック・リミテッド Polycationic sterol derivatives as transfection agents
US6133233A (en) * 1997-02-18 2000-10-17 Kansas State University Research Foundation Peptide modulation of reperfusion injury
NL1008139C2 (en) 1998-01-27 1999-07-28 Stichting Tech Wetenschapp Antimicrobial peptides.
US6767904B2 (en) 1998-03-06 2004-07-27 Bringham Young University Steroid derived antibiotics
NL1010692C2 (en) * 1998-12-01 2000-06-06 Stichting Tech Wetenschapp Antiviral peptides.
CN101378761B (en) * 2006-02-01 2013-10-16 杨百翰大学 Cationic steroid antimicrobial compositions and methods of use
WO2008048340A2 (en) 2006-02-01 2008-04-24 Brigham Young University Cationic steroid antimicrobial compositions for treating poxvirus infections
US20070190558A1 (en) 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Antimicrobial Compositions and Methods of Use
JP2007314432A (en) * 2006-05-23 2007-12-06 Japan Science & Technology Agency Novel antibacterial peptide and serum-free medium containing the antibacterial peptide as an active ingredient
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US11083735B2 (en) 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
US20210186989A1 (en) * 2018-06-06 2021-06-24 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Enhanced trained immunity in myeloid cells by ship-1 inhibition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006597A1 (en) * 1987-03-04 1988-09-07 The United States Of America, As Represented By Th New synthetic bioactive compounds and method of producing bioactive effect
WO1993005802A1 (en) * 1991-09-13 1993-04-01 Magainin Pharmaceuticals Inc. Biologically active amphiphilic peptide compositions and uses therefor
WO1993024138A1 (en) * 1992-06-01 1993-12-09 Magainin Pharmaceuticals, Inc. Biologically active peptides having n-terminal substitutions
WO1994005313A1 (en) * 1992-08-31 1994-03-17 Magainin Pharmaceuticals Inc. Treatment of gynecological malignancies with biologically active peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006597A1 (en) * 1987-03-04 1988-09-07 The United States Of America, As Represented By Th New synthetic bioactive compounds and method of producing bioactive effect
WO1993005802A1 (en) * 1991-09-13 1993-04-01 Magainin Pharmaceuticals Inc. Biologically active amphiphilic peptide compositions and uses therefor
WO1993024138A1 (en) * 1992-06-01 1993-12-09 Magainin Pharmaceuticals, Inc. Biologically active peptides having n-terminal substitutions
WO1994005313A1 (en) * 1992-08-31 1994-03-17 Magainin Pharmaceuticals Inc. Treatment of gynecological malignancies with biologically active peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABOUDY, Y. ET AL: "Activity of two synthetic amphiphilic peptides and magainin -2 against herpes simplex virus types 1 and 2", INT. J. PEPT. PROTEIN RES. (1994), 43(6), 573-82 *
CUERVO, JULIO H. ET AL: "The magainins: sequence factors relevant to increased antimicrobial activity and decreased hemolytic activity", PEPT. RES. (1988), 1(2), 81-6 *

Also Published As

Publication number Publication date
WO1996008270A2 (en) 1996-03-21
AU3512595A (en) 1996-03-29

Similar Documents

Publication Publication Date Title
WO1996008270A3 (en) Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
MY121276A (en) Use of glp-1 or analogs to abolish catabolic changes after surgery
AU2176395A (en) Compositions for treatment of diabetic complications
AU1128297A (en) Composition for treating pain
CA2168963A1 (en) Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
SI0771788T1 (en) Substituted sulphonimidamides, method for their preparation, their use as medicament or diagnostic and medicament containing them
AU5022096A (en) Lipid constructs for targeting to vascular smooth muscle tissue
WO1997048369A3 (en) Prophylactic and therapeutic treatment of skin sensitization and irritation
WO2000035952A3 (en) Compounds for control of eating, growth and body weight
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
EP0287204A3 (en) Silver sulfadiazine useful for inhibiting the transmission of the aids virus
AU4440496A (en) Use of src SH2 specific compounds to treat a bone resorption disease
AU3263795A (en) Medicament for treatment or prophylaxis of incontinence
AU7639796A (en) Novel drug for relieving pain and promoting the removal of calculi in urolithiasis
AU5713196A (en) Method for treatment of pain
AU5699396A (en) Compositions for the treatment of skin conditions
WO2002067851A3 (en) Method for treating fibrotic diseases or other indications iiic
AU6922994A (en) Use of acylcarnitin to treat illnesses caused by aids
AU5624796A (en) Diagnostic and treatment methods relating to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
AU8051891A (en) Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it
AU6038196A (en) Compositions and methods of treating il-6 associated disease s
AU1457092A (en) An agent for animal skin treatment
AU6345096A (en) Improved prosthesis for human forearm
HUP9900313A3 (en) Use of anti-oestrogens as male contraceptives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1-56,DESCRIPTION,REPLACED BY NEW PAGES 1-52;PAGES 57-59,CLAIMS,REPLACED BY NEW PAGES 53-55;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase